Strategy
Rather than focus on a single product or indication, the larger opportunity lies in building a robust and diverse product pipeline of high-value potential drug candidates to treat psychiatric illnesses. We are an Intellectual Property (IP) Centric Company. IP is at the center of everything we do. We believe it is management's responsibility to invest tens of millions of dollars to develop product candidates that have a strong, proven intellectual property base.
Featured patent
Non-Hallucinogenic Psychedelic fungi
We announce the issuance of a landmark patent (US 12,697.362) relating to proprietary, non-hallucinogenic psilocybin "magic mushrooms" and are seeking strategic partnerships with leading nutraceutical, supplement, pharmaceutical, and venture groups to bring breakthrough products to market, potentially opening a billion-dollar-plus opportunity.
This foundational patent paves the way for the development of a portfolio of products with massive global market potential. Our invention makes it possible to produce a stable, fertile, true-breeding mushroom of Psilocybe Cubensis without producing either hallucinogenic compound, psilocybin or psilocin.
Because our patented technology results in a non-hallucinogenic substance, these products do not require regulatory approval. This opens the door for much faster commercialization into a large market. On a longer horizon, this patent also may lead the way to the development of pharmaceuticals through synthetic biology.
For more information, view our commentary:
"When It Comes To Magic Mushrooms, Less Is More."
Development strategy
Partnering is a key part of our strategy and our team of drug hunters is continuously on the lookout for innovative technologies and assets with strong patents. We take a broad, multi-pronged approach to identify drugs that can be repurposed as drug candidates for psychiatric disorders.
Our pipeline development strategy reflects a blended approach to manage risk and catalyze partnerships that enable access to non-dilutive capital, and increase speed.
Team History - Repurposing
Drug repurposing refers to the process of identifying new indications for existing FDA-approved drugs, product candidates under development, and abandoned compounds. The advantage of repurposing is that it significantly reduces the time required for development since the safety of the compound has often been tested. In fact, approximately 30 percent of repurposed drugs ultimately reach patients, which is a substantial improvement compared to the 10 percent success rate of the traditional drug development process.
Our team has successfully worked together to repurpose drugs and devices in several other successful companies like these below and has created significant value for patients and stakeholders.
Artificial intelligence (AI)
Drug repurposing depends on massive observed data from existing drugs and diseases. We utilize AI approaches for the systematic identification of drug repurposing leads based on big data resources.
AI plays a crucial role in providing researchers with tools to model and navigate the biological networks in which drug targets reside. AI of various architectures, themselves inspired by neural networks, learn and expose the implicit rules that govern the performance of biological pathways in health and disease. AI also provides us with predictions of previously unknown connections identifying successful new drug-target combinations.
In-Licensing Drug Programs
Often, pharmaceutical and biotech companies decide to curtail programs that are no longer a priority due to business decisions and not for scientific reasons. Many of these programs are fairly advanced, from a development prospective, where much of the early clinical work has been performed, and the drug is ready for further clinical testing.
In the current financial environment, in-licensing opportunities offer additional advantages to companies who need to focus on their primary assets, while maintaining an investment in their original work. This offers us a unique situation to in-license these advanced assets.
We are able to move quickly to a clinically viable drug, which provides a substantial cost savings. This strategy has the advantage of de-risking the early stages of drug discovery and development, which ultimately will lead to a more rapid timeline to achieving a ROI.
pharmaceutical patents
We seek "composition of matter" patents, also called product patents – the strongest possible type of patent which is not circumventable. This is what our substantial partners require.
We are not proponents of formulation, crystalline forms, and process patents. Our product candidates meet the stringent criteria for partnering with Big Pharma.
